



ASX ANNOUNCEMENT

3 December 2020

Cleansing Statement

CardieX Limited (ASX: CDX) (CardieX, the Company), advises that on 3 December 2020, it announced an intention to offer eligible shareholders the opportunity to subscribe for up to \$30,000 of new fully paid ordinary shares in the Company under a Share Purchase Plan (SPP) pursuant to ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (the ASIC Instrument).

The Company hereby gives notice, in accordance with the ASIC Instrument, that:

- a) the Company will make offers to issue shares under a Share Purchase Plan without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (the Corporations Act);
- b) as at the date of this notice, the Company has complied with the provisions of:
 - a. Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Section 674 of the Corporations Act; and
- c) As at the date of this notice there is no information:
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the body; or
 - ii. the rights and liabilities attaching to the relevant securities

to the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document.

Authorised for release by the Board of Directors, and released by Jarrod White

For more information please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com

**About CardieX**

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. The company's ATCOR division is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR·X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).